The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells.
about
Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells.The role of apoptosis repressor with a CARD domain (ARC) in the therapeutic resistance of renal cell carcinoma (RCC): the crucial role of ARC in the inhibition of extrinsic and intrinsic apoptotic signalling.S6K1 inhibition enhances the apoptotic cell death of breast cancer cells in response to Bcl-2/Bcl-xL inhibition by the downregulation of survivinThe ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skinMUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors.High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.Dichloroacetate and metformin synergistically suppress the growth of ovarian cancer cells.Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP.Imperatorin acts as a cisplatin sensitizer via downregulating Mcl-1 expression in HCC chemotherapy.Msi1 confers resistance to TRAIL by activating ERK in liver cancer cells.Enhanced Mitochondrial Transient Receptor Potential Channel, Canonical Type 3-Mediated Calcium Handling in the Vasculature From Hypertensive Rats.Curcumin enhances the antitumor effect of ABT-737 via activation of the ROS-ASK1-JNK pathway in hepatocellular carcinoma cells.Mcl-1 Is a Novel Target of miR-26b That Is Associated with the Apoptosis Induced by TRAIL in HCC Cells.Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers.Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma.
P2860
Q33431526-D67EAB40-4529-4641-A6BF-A99C5EC6F92BQ33629783-A8B16843-02B6-4BE8-B97B-A0D376376B74Q35870533-97E600AB-753D-4474-98CC-FC19E6E4CB7BQ35966223-B29E54F5-82D9-4F08-A6D2-C5D693A28FCDQ36928457-B5440A66-0D23-4251-8B6E-FC14385F36A8Q37317447-8B6D787D-9338-4339-871C-62560B7EA208Q37644880-B4E90103-14B0-41D7-A811-E8DF8ECECEAEQ37718693-62C3B854-CCE3-4928-B68E-D49360C641D7Q38848505-21E6D31B-0B12-4507-B0B4-10AE7D3FD655Q38902765-E1C96B6B-DFA9-4EE5-B68F-C22F64270E4EQ41627358-33CCA261-F73D-47A5-AB1C-564EF6A627E3Q41853724-A60E8265-466C-4A7F-B984-9A0C91F7F8ECQ42180490-18FEE451-C0DA-42E8-A7D4-05151BFA14ECQ49988930-2D348B99-475F-4752-B2D4-8FDB6013696EQ52571263-44D120EB-EC54-4386-B009-768DABE0CFFD
P2860
The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The Bcl-2/xL inhibitor ABT-263 ...... epatocellular carcinoma cells.
@ast
The Bcl-2/xL inhibitor ABT-263 ...... epatocellular carcinoma cells.
@en
type
label
The Bcl-2/xL inhibitor ABT-263 ...... epatocellular carcinoma cells.
@ast
The Bcl-2/xL inhibitor ABT-263 ...... epatocellular carcinoma cells.
@en
prefLabel
The Bcl-2/xL inhibitor ABT-263 ...... epatocellular carcinoma cells.
@ast
The Bcl-2/xL inhibitor ABT-263 ...... epatocellular carcinoma cells.
@en
P2093
P2860
P356
P1433
P1476
The Bcl-2/xL inhibitor ABT-263 ...... epatocellular carcinoma cells.
@en
P2093
Fengtian He
Jiqin Lian
Xufang Dai
Zhenhong Ni
P2860
P2888
P356
10.1186/1476-4598-13-98
P577
2014-04-30T00:00:00Z
P5875
P6179
1029729780